HeartBeam (NASDAQ: BEAT) reported third-quarter 2025 results and highlighted continued progress toward commercialization of its 12-lead ECG synthesis software, now in the final stage of FDA 510(k) review with anticipated clearance by year end. The company is advancing commercial readiness, including a new partnership with HeartNexus for 24/7 cardiologist review services, alongside new scientific data presented at AHA Scientific Sessions and HRX Live 2025 and an expanded global IP portfolio of 24 issued patents. For the quarter, R&D expenses were $3.3 million, G&A expenses were $2.0 million, net loss was $5.3 million and cash totaled $1.9 million. HeartBeam will discuss its results and provide a business update during a conference call and webcast on Nov. 13 at 4:30 p.m. ET.
To view the full press release, visit https://nnw.fm/pnnUx
At a glance
- Company
- HeartBeam, Inc.
- Ticker
- NASDAQ: BEAT
- Announcement
- Earnings
Key figures
- R&D expenses
- $3.3 million
- G&A expenses
- $2.0 million
- Net loss
- $5.3 million
- Cash
- $1.9 million
- Issued patents
- 24
Products and programs
About HeartBeam, Inc.
HeartBeam, Inc. is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024. The 12-Lead ECG synthesis software is under FDA review. The Company holds over 20 issued patents related to technology enablement.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
In brief
HeartBeam reported third-quarter 2025 results and said its 12-lead ECG synthesis software is in the final phase of FDA 510(k) review, with clearance anticipated by year end. The company also described preparations for commercialization, including an agreement with HeartNexus to provide round-the-clock cardiologist review services. HeartBeam said new scientific data was presented at AHA Scientific Sessions and HRX Live 2025, and that its global intellectual property portfolio includes 24 issued patents. For the quarter, it reported research and development expenses of $3.3 million, general and administrative expenses of $2.0 million, a net loss of $5.3 million, and cash of $1.9 million. The company said it would discuss results and provide an update on a conference call and webcast.
Key takeaways
- HeartBeam says its 12-lead ECG synthesis software has reached the final stage of FDA 510(k) review.
- The company anticipates FDA clearance by year end.
- HeartNexus will provide 24/7 cardiologist review services under a new partnership.
- HeartBeam reported a $5.3 million net loss and $1.9 million in cash for the quarter.
